INVESTORS & MEDIA

Events & Presentations

Archived Events
Nov 3 - Nov 4

These slides contain the 48-week data from the Phase 2/3 PHOTON study (by Dr. David M. Brown) and the Phase 3 PULSAR study (by Jean-François Korobelnik) of aflibercept 8 mg for DME and nAMD, respectively, as presented at the 55th Annual Scientific Session of The Retina Society on November 3-4, 2022.

Sep 302022 4:24 PM EDT Sep 30, 2022 | 4:24 PM EDT

These slides contain the 48-week results from the Phase 2/3 PHOTON study (by Dr. David M. Brown) and the Phase 3 PULSAR study (by Dr. Paolo Lanzetta) of aflibercept 8 mg for DME and nAMD, respectively, as presented at AAO 2022 on September 30, 2022.

Sep 122022 8:00 AM EDT Sep 12, 2022 | 8:00 AM EDT
Feb 122022 10:00 AM EST Feb 12, 2022 | 10:00 AM EST

These slides contain the Ph2 CANDELA data through week 44. The full CANDELA presentation was given by Dr. David M. Brown at Angiogenesis, Exudation, and Degeneration 2022 on February 12, 2022.